Prevalence Of Psychotropic Polypharmacy-Evaluation On Advocation And Limitation

Authors

  • Rachamsetty kavya , Senthil Raj R

DOI:

https://doi.org/10.47750/pnr.2022.13.S10.313

Abstract

Patients with newly diagnosed chronic diseases, notably cancer, frequently utilize psychiatric medicines for their mental support. A minimum of 90 days of continuous usage of two or more kinds of psychotropic medications was required to be considered psychiatric polypharmacy. However, little is known about how psychotropic polypharmacy affects the use of healthcare services during the first stage of medical treatment. Antipsychotic Polypharmacy is often combined of CNS stimulants or atomoxetine, antidepressants (selective serotonin reuptake inhibitors, selective serotonin norepinephrine reuptake inhibitors, serotonin modulators, and tricyclic antidepressants), antipsychotic agents (first- and second-generation agents), lithium, anticonvulsant mood stabilizers (such as divalproex, oxcarba. As operational definitions of polypharmacy became stricter, the observed rate of polypharmacy decreased. The results imply that when comparing rates of polypharmacy among studies with different operational definitions, significant discrepancies occur. Even while community-dwelling older people with mental problems usage of psychotropic polypharmacy is lower than in nursing homes and home healthcare settings, thorough monitoring is still necessary to prevent significant side effects in this sensitive group. This review covers the incidence of polypharmacy in various nations while taking antipsychotics as well as other medication types. More research is required to completely understand the long-term psychotropic polypharmacy use pattern, the clinical justifications for its use, and the effects of this therapeutic approach when applied to patients with a variety of chronic illnesses and mental disorders.

Downloads

Published

2022-12-31 — Updated on 2022-12-31

Issue

Section

Articles

How to Cite

Prevalence Of Psychotropic Polypharmacy-Evaluation On Advocation And Limitation. (2022). Journal of Pharmaceutical Negative Results, 2628-2633. https://doi.org/10.47750/pnr.2022.13.S10.313